Kairos Pharma, Ltd. (NYSE American: KAPA) announced its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, highlighting new data on its investigational small molecule GITR ligand agonist KROS 101. The ASCO meeting was held from May 30 to June 3, 2025, in Chicago, Illinois.
The presentation, titled 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,' demonstrated KROS 101’s capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action. The study showed KROS 101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, boosting cytokine production and tumor cancer cell killing.
Furthermore, the study found that KROS 101 reduced T reg-mediated suppression by decreasing T reg populations, which reverses immune system suppression and enhances effector T cell activity. KROS 101 also showed superiority to the anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity, and preventing T cell exhaustion, strongly supporting its continued study as a cancer immunotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.